Lumos Pharma, Inc. (LUMO)
Lumos Pharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Austin, TX, US. The stock last traded at $4.34, up 0.00% on the session, giving a market capitalisation of $37.5M. On trailing twelve-month figures it carries a trailing P/E of -1.04, a net margin of -1659.4%. Its beta of 0.33 implies it has historically moved less than the broad market.
Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug candidate is being investigated for its potential in treating pediatric growth hormone deficiency and various other uncommon endocrine conditions. The company's operations are based in Austin, Texas.
Lumos Pharma, Inc. is most often compared with the following Healthcare names: